Anavex Life Sciences Corp.
AVXL Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 26, 2026
$1.28
KIRA · Stoqly’s AI analyst, in plain words
- Anavex Life Sciences Corp. had $4.7M of revenue in fiscal 2025, down 36.1% on the year before. Over five years, revenue changed +91.8% a year on average.
- Its operating margin was −1,098.9%, down 376.6 pts: of every 100 in sales, about −1,099 is left after running the business.
- Anavex Life Sciences Corp. lost $46.4M in fiscal 2025.
Market cap
$118.9B
P/E
—
Revenue
$4.7M
Net income
−$46.4M
Free cash flow
—
Operating margin
−1,098.9%
Anavex Life Sciences Corp. in 30 seconds · fiscal 2025
Are sales growing?
−36.1%
No. Sales fell 36.1% last year.
Does it make a profit?
−991.4%
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Anavex Life Sciences Corp. does
No business description yet.
- Fiscal year ends
- September 30, 2025
- Latest annual report
- 10-K · Nov 25, 2025
- Legal name
- ANAVEX LIFE SCIENCES CORP.
- CIK
- 0001314052
Anavex Life Sciences Corp. · AVXL
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.0M | $0.9M | $6.5M | $7.3M | $4.7M |
| Revenue growth | −85.6% | 3,542.3% | 588.4% | 12.3% | −36.1% |
| Net interest income | $0.0M | $0.9M | $6.5M | $7.3M | $4.7M |
| Operating margin | −161,546.2% | −5,383.9% | −855.4% | −722.4% | −1,098.9% |
| Net income | −$37.9M | −$48.0M | −$47.5M | −$43.0M | −$46.4M |
| Net margin | −145,803.8% | −5,066.3% | −728.7% | −587.5% | −991.4% |
| Diluted EPS | −$0.54 | −$0.62 | −$0.60 | −$0.52 | −$0.54 |
| Cash | |||||
| Cash from operations | −$30.4M | −$24.2M | −$27.8M | −$30.8M | −$39.0M |
| Share count change | 19.9% | 10.2% | 3.7% | 4.6% | 2.2% |
| Debt and strength | |||||
| Cash and short-term investments | $152M | $149M | $151M | $132M | $103M |
| Shareholders' equity | $151M | $142M | $142M | $120M | $94.9M |
| Returns and quality | |||||
| Return on equity | −42.6% | −32.7% | −33.4% | −32.8% | −43.1% |
| Return on tangible equity | −25.1% | −33.7% | −33.5% | −35.8% | −48.9% |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Anavex Life Sciences Corp. · AVXL
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.28 a share, the company is worth $118.9B.
Source: SEC EDGAR XBRL filings (CIK 0001314052). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.